Finance

Lists
NTLA:NASDAQ
Intellia Therapeutics Inc
$11.94
+6.23%
(+0.70) 1D
$11.96
+0.17% (+0.020)
Pre-market
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
$11.88
High
$12.08
Low
$11.47
Mkt. cap
1.67B
Avg. vol.
4.39M
Volume
18.56K
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.36
Beta
1.81
Shares outstanding
140.13M
No. of employees
377
Open
$11.88
High
$12.08
Low
$11.47
Mkt. cap
1.67B
Avg. vol.
4.39M
Volume
18.56K
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.36
Beta
1.81
Shares outstanding
140.13M
No. of employees
377
News stories
From sources across the web
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com
Analyst ratings
Based on 15 analysts giving stock ratings to NTLA in the past 3 months
Hold
Buy
6
Hold
6
Sell
3
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for NTLA in the last 3 months.
Highest
Current $11.94
$49.00 (+310.39%)
Average
$19.15 (+60.39%)
Lowest
$8.00 (-33.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$49.00
+310.4%
08/06/2026
Salveen Richter
Goldman Sachs
Sell
Maintained
$9.00
-24.6%
08/06/2026
Jonathan Miller
Evercore ISI
Buy
Upgraded
$24.00
+101%
08/07/2026
Luca Issi
RBC Capital
Hold
Maintained
$15.00
+25.6%
08/06/2026
Alec Stranahan
Bank of America Securities
Hold
Reiterated
$17.00
+42.4%
08/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+109.4%
08/07/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/06/2026
Andy Chen
Wolfe Research
Sell
Downgraded
$9.00
-24.6%
07/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
$17.00
+42.4%
07/10/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
06/14/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$29.00
+142.9%
05/27/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
$8.00
-33%
05/13/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$15.00
+25.6%
05/13/2026
William Pickering
Bernstein
Hold
Reiterated
$17.00
+42.4%
05/13/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$15.00
+25.6%
05/12/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$30.00
+151.3%
04/28/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
$30.00
+151.3%
04/27/2026
Mani Foroohar
Leerink Partners
Buy
Reiterated
$35.00
+193.1%
04/27/2026
Jack Allen
Robert W. Baird
Hold
Maintained
$13.00
+8.9%
04/27/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.78M
23.02M
15.05M
7.66M
Cost of goods sold
78.95M
73.63M
80.74M
-
Cost of revenue
78.95M
73.63M
80.74M
-
Research and development expenses
-
-
-
82.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
46.31M
48.10M
34.84M
37.82M
Operating expense
46.31M
48.10M
34.84M
120.42M
Total operating expenses
125.26M
121.73M
115.58M
120.42M
Operating income
-111.48M
-98.71M
-100.53M
-112.76M
Other non operating income
-
-
-
-
EBT including unusual items
-101.32M
-95.79M
-96.23M
-106.63M
EBT excluding unusual items
-104.76M
-92.23M
-95.33M
-106.96M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-101.32M
-95.79M
-96.23M
-106.63M
Net profit margin
-735.19%
-416.15%
-639.49%
-1,392.27%
Earnings per share
-0.92
-0.83
-0.81
-0.80
Interest and investment income
6.71M
6.48M
5.20M
5.80M
Interest expense
-
-
-
-
Net interest expenses
6.71M
6.48M
5.20M
5.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-109.06M
-96.33M
-98.33M
-110.56M
Gain or loss from assets sale
-
527.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps